Ali Fattaey

Medicine · Health Sciences

22h-index7.8kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(18), Virus-based gene therapy research(14), Histone Deacetylase Inhibitors Research(10), Epigenetics and DNA Methylation(7), Protein Degradation and Inhibitors(6)

Publications47 total

Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Data from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2023Open Access
Abstract 2326: Preclinical characterization of MTB-9655, a first-in-class, clinical stage ACSS2 inhibitor
Cancer Research·2022· 1 cited
Abstract 1397: A phenotypic-based drug discovery approach against tumors with MTAP loss
Cancer Research·2022
Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
Journal of Clinical Oncology·2022· 11 cited
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
Molecular Cancer Therapeutics·2016· 138 cited
The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL
Blood·2016· 4 cited
Abstract 4634: Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies
Cancer Research·2016
A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma
Blood·2013· 7 cited
Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P).
Molecular Cancer Therapeutics·2011
Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.
Journal of Clinical Oncology·2011· 9 cited
Pharmacokinetic and pharmacodynamic analysis of gastric cancer patients treated with telatinib.
Journal of Clinical Oncology·2011· 2 cited
137 Preclinical characterization of ACTB-1010, an orally activity Aurora kinase inhibitor
European Journal of Cancer Supplements·2010
141 ACTB-1003 - a unique oral pan FGFR and PI3K pathway inhibitor with divergent modes of activity
European Journal of Cancer Supplements·2010
ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K).
Journal of Clinical Oncology·2010· 4 cited
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
PubMed·2003· 36 cited
page 1 of 3Next →

Frequent Co-authors

Kristian Helin(9), Kaiming Sun(9), Ruzanna Atoyan(9), Mylissa Borek(9), Steven DellaRocca(9), David Tuck(9), Maria Samson(8), Guang-Xin Xu(8), Troy Patterson(8), Jaye L. Viner(8), E Harlow(6), W. Anna(6), Michelle D. Garrett(5), Lori Kunkel(5), Amy Burd(4), Julie A. Nye(3), Adam Sampson-Johannes(3), Frank McCormick(3), Nicholas J. Dyson(3), Terry Hermiston(3)